Form D · Biotechnology
FATE THERAPEUTICS INC
San Diego, CA · CIK 0001434316
Offering snapshot reported Jul 6, 2020 · SEC filing
- Reported sold
- $50M Offering amount: $50M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 24, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 6, 2020 | Initial | $49,999,989 | No comparison | 1 | SEC filing |
| Apr 21, 2020 | Initial | $50,000,024 | No comparison | 1 | SEC filing |
| Dec 8, 2016 | Initial | $56,749,988 | No comparison | 21 | SEC filing |
| Aug 19, 2016 | Initial | $10,290,000 | No comparison | 4 | SEC filing |
| May 18, 2015 | Initial | $8,000,000 | No comparison | 1 | SEC filing |
| Aug 13, 2013 | Initial | $20,000,000 | No comparison | 3 | SEC filing |
| Aug 21, 2012 | Initial | $9,244,679 | No comparison | 17 | SEC filing |
| Apr 20, 2011 | Amendment | $35,988,360 | $3,500,000vs Dec 24, 2009 | 18 | SEC filing |
| Apr 20, 2011 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
| Dec 24, 2009 | Amendment | $32,488,360 | $2,000,000vs Nov 23, 2009 | 16 | SEC filing |
| Nov 23, 2009 | Initial | $30,488,360 | No comparison | 16 | SEC filing |
| May 2, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| May 2, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-370287
Source: Form D, filed Jul 6, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Stewart Abbot | Executive |
| Shefali Agarwal | Director |
| Timothy Coughlin | Director |
| Mark J. Enyedy | Director |
| Robert Epstein | Director |
| Paul Grayson | Director, Executive |
| Robert Hershberg | Director |
| Karin Jooss | Director |
| Michael Lee | Director |
| John Mendlein | Director |
| Amir Nashat | Director |
| Robert Nelsen | Director |
| William Rastetter | Director |
| Bryan Roberts | Director |
| Daniel D. Shoemaker | Executive |
| Chris Storgard | Executive |
| Cindy Tahl | Executive |
| Carl Weissman | Director |
| Christian Weyer | Director, Executive |
| J. Scott Wolchko | Director, Executive |
| Scott Wolchko | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3535 General Atomics Court Suite 200
San Diego, CA, 92121
San Diego, CA, 92121